
- /
- Supported exchanges
- / US
- / OCEA.PINK
Ocean Biomedical Inc. (OCEA PINK) stock market data APIs
Ocean Biomedical Inc. Financial Data Overview
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ocean Biomedical Inc. data using free add-ons & libraries
Get Ocean Biomedical Inc. Fundamental Data
Ocean Biomedical Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-08
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ocean Biomedical Inc. News

Ocean Biomedical faces license terminations over breaches
Ocean Biomedical, Inc. is grappling with the termination of significant license agreements after failing to meet various obligations. On June 9, 2025, Elkurt, Inc. notified the company of the terminat...


Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, ...

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly publi...

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received ad...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.